Related Experiment Videos
Marburg virus vaccines: comparing classical and new approaches
M Hevey1, D Negley, L VanderZanden
1Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.
Abstract:
An effort to develop a safe and effective vaccine for Marburg virus (MBGV), one of the filoviruses known to cause high mortality rates in humans, led us to compare directly some of the merits of modern versus classical vaccine approaches for this agent. Prior work had established the MBGV-glycoprotein (GP), the only known virion surface antigen, as a candidate for inclusion in a vaccine. In this study, we vaccinated groups of Hartley guinea pigs with killed MBGV, live attenuated MBGV, soluble MBGV-GP expressed by baculovirus recombinants, MBGV-GP delivered as a DNA vaccine, or MBGV-GP delivered via an alphavirus RNA replicon. Serological responses were evaluated, and animals were challenged with a lethal dose of MBGV given either subcutaneously or via aerosol. Killed MBGV and replicon-delivered MBGV-GP were notably immunogenic and protective against MBGV, but results did not exclude any approach and suggested a role for DNA vaccines in immunological priming.
Insights
Researchers compared vaccine strategies for Marburg virus (MBGV), a deadly filovirus. Killed MBGV and RNA replicon vaccines showed strong protection, suggesting diverse approaches may be viable for MBGV vaccine development.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Marburg virus (MBGV) is a filovirus causing high human mortality.
- The MBGV-glycoprotein (GP) is a key target for vaccine development.
Purpose of the Study:
- To compare the efficacy of different vaccine approaches for Marburg virus.
- To evaluate modern versus classical vaccine strategies against MBGV.
Main Methods:
- Groups of guinea pigs were vaccinated with killed MBGV, live attenuated MBGV, soluble MBGV-GP (baculovirus recombinant), DNA vaccine (MBGV-GP), or RNA replicon vaccine (MBGV-GP).
- Serological responses were assessed, and animals were challenged with a lethal dose of MBGV via subcutaneous or aerosol routes.
Main Results:
- Killed MBGV and RNA replicon-delivered MBGV-GP vaccines demonstrated significant immunogenicity and protection against lethal MBGV challenge.
- All tested vaccine approaches elicited some immune response, indicating potential for various strategies.
Conclusions:
- Killed MBGV and RNA replicon vaccines are effective against Marburg virus infection.
- DNA vaccines may play a role in immunological priming for MBGV vaccination.